BR9813391C1 - processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo - Google Patents

processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo

Info

Publication number
BR9813391C1
BR9813391C1 BRPI9813391A BR9813391A BR9813391C1 BR 9813391 C1 BR9813391 C1 BR 9813391C1 BR PI9813391 A BRPI9813391 A BR PI9813391A BR 9813391 A BR9813391 A BR 9813391A BR 9813391 C1 BR9813391 C1 BR 9813391C1
Authority
BR
Brazil
Prior art keywords
epo
epo composition
specific activity
composition
produce
Prior art date
Application number
BRPI9813391A
Other languages
English (en)
Other versions
BR9813391A (pt
Inventor
Haselbeck Anton
Koll Hans
Burg Josef
Sellinger Karl-Heinz
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BR9813391A publication Critical patent/BR9813391A/pt
Publication of BR9813391C1 publication Critical patent/BR9813391C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<b><mu>composição de epo, preparado farmacêutico, e processos para produzir uma composição de epo e para aumentar a atividade específica de uma composição de epo<mv><d> a invenção relaciona-se com novas composições de epo dotadas de alta atividade específica, as quais são caracterizadas por uma alta proporção de unidades de n-acetil- lactosamina e/ou ramificações tetraantenárias na estrutura de carboidrato. além disso, a invenção relaciona-se com um processo para produzir esses produtos de epo.
BRPI9813391A 1997-12-03 1998-12-03 processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo BR9813391C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
EP98113415 1998-07-17
PCT/EP1998/007876 WO1999028346A1 (de) 1997-12-03 1998-12-03 Erythropoietin mit hoher spezifischer aktivität

Publications (2)

Publication Number Publication Date
BR9813391A BR9813391A (pt) 2000-10-10
BR9813391C1 true BR9813391C1 (pt) 2021-05-25

Family

ID=26042142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9813391A BR9813391C1 (pt) 1997-12-03 1998-12-03 processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo

Country Status (12)

Country Link
US (1) US7659373B2 (pt)
EP (1) EP1037921B1 (pt)
JP (3) JP4220125B2 (pt)
KR (1) KR100390325B1 (pt)
CN (1) CN1280309C (pt)
AR (1) AR022358A1 (pt)
AU (1) AU744086B2 (pt)
BR (1) BR9813391C1 (pt)
CA (1) CA2309810C (pt)
ES (1) ES2523599T3 (pt)
TR (1) TR200001580T2 (pt)
WO (1) WO1999028346A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002247896A1 (en) * 2002-03-26 2003-10-08 Lek Pharmaceutical And Chemical Company D.D. Process for the preparation of a desired erythropoietin glyco-isoform profile
PT1543106E (pt) 2002-07-15 2007-05-31 Immunex Corp Métodos e meios para controlar a sialilação de proteínas produzidas por células de mamíferos
KR100473658B1 (ko) * 2002-10-25 2005-03-10 드림바이오젠 주식회사 위치 선택적 수식법에 의한 혼성형 단백질 치료제 개발을 위한 형질전환 효모 시스템
KR100473659B1 (ko) * 2002-10-25 2005-03-15 드림바이오젠 주식회사 당사슬 위치에 위치선택적 수식법으로 유용한 고분자를수식시킨 혼성형 단백질의 제조방법
JP4865539B2 (ja) 2003-05-09 2012-02-01 クルセル ホランド ベー ヴェー Ｅ１不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法
DE102004027816A1 (de) 2004-06-08 2006-01-05 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von Erythropoietin
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
US8255487B2 (en) * 2008-05-16 2012-08-28 Integrated Illumination Systems, Inc. Systems and methods for communicating in a lighting network
CA2736141C (en) * 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
KR20120117728A (ko) 2009-09-23 2012-10-24 바이오제너릭스 에이지 재조합 인간 에리트로포이에틴(ｅｐｏ)의 정제 방법, 이렇게 정제된 ｅｐｏ 및 이를 포함하는 약학적 조성물
US8951807B2 (en) 2010-01-15 2015-02-10 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
US8895707B2 (en) * 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
JP5918697B2 (ja) 2010-10-15 2016-05-18 Ｊｃｒファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
JP5881744B2 (ja) 2011-02-02 2016-03-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド アルカリ溶液でのアパタイトの表面中和方法
KR101443257B1 (ko) 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
WO2013180933A1 (en) 2012-05-30 2013-12-05 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
US10099157B2 (en) 2014-06-23 2018-10-16 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
WO2015200282A1 (en) 2014-06-23 2015-12-30 Bio-Rad Laboratories, Inc. Apatite pretreatment
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
US20230331798A1 (en) * 2020-09-22 2023-10-19 Jecho Laboratories, Inc. Glycosylation-modified erythopoietin and use thereof
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
DE4028800A1 (de) * 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5459031A (en) * 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
AU706304B2 (en) * 1994-11-01 1999-06-10 Kirin Pharma Kabushiki Kaisha Peptide sequence that forms mucin sugar chain and technique for modifying protein to be linked with mucin sugar chain
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
EP0986644B1 (de) 1997-07-23 2006-10-04 Boehringer Mannheim GmbH Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren

Also Published As

Publication number Publication date
JP4234647B2 (ja) 2009-03-04
JP2003238593A (ja) 2003-08-27
CA2309810A1 (en) 1999-06-10
JP3673261B2 (ja) 2005-07-20
AU2158199A (en) 1999-06-16
WO1999028346A1 (de) 1999-06-10
CA2309810C (en) 2014-07-08
CN1280309C (zh) 2006-10-18
TR200001580T2 (tr) 2000-12-21
EP1037921A1 (de) 2000-09-27
EP1037921B1 (de) 2014-09-24
JP2004339234A (ja) 2004-12-02
KR100390325B1 (ko) 2003-07-07
ES2523599T3 (es) 2014-11-27
AR022358A1 (es) 2002-09-04
AU744086B2 (en) 2002-02-14
JP2001525338A (ja) 2001-12-11
US20050288220A1 (en) 2005-12-29
BR9813391A (pt) 2000-10-10
US7659373B2 (en) 2010-02-09
CN1280586A (zh) 2001-01-17
KR20010024681A (ko) 2001-03-26
JP4220125B2 (ja) 2009-02-04

Similar Documents

Publication Publication Date Title
BR9813391C1 (pt) processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo
FI903978A0 (fi) Glasfiber som soenderfaller i fysiologisk omgivning.
BR9801126A (pt) 1,4-benzotiazepina-1,1-dióxidos hipolipidêmicos.
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
ATE313642T1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
ATE315050T2 (de) Verfahren zur herstellung von mehrfach vernetzten hyaluronsäurederivaten
ITPD940042A0 (it) Processo per la preparazione di acido ialuronico mediante sintesi enzimatica e relative composizioni farmaceutiche
PT99055A (pt) Processo para a preparacao de novas aminas alquil-heterociclicas e de composicoes farmaceuticas que as contem
FR2623423B1 (fr) Nouveaux catalyseurs a base de zeolithes modifiees par des elements alcalins sous forme metallique, leur preparation et leur application a l&#39;alkylation des derives alkyl-aromatiques
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
BRPI9814894A (pt) processo para a preparação de ácidos 8-metóxi-quinolonocarboxílicos.
BR9811923A (pt) Compostos possuindo atividade neuronal
DE69020979D1 (de) Neue Arginin-Deiminase, Verfahren zu ihrer Herstellung und ein Antikrebsmittel, das dieses Enzym als wirksamen Bestandteil enthält.
ES2131972T3 (es) Derivados de sulfamato de derivados del 1,3,5(10)-estratrieno, procedimiento para su fabricacion y composiciones farmaceuticas que contienen estos compuestos.
BR9402089A (pt) Composição para cuidado da pele e processo para melhorar as propriedades de irritação provocada por retinol
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
ITRM910554A1 (it) Composizioni farmaceutiche stabilizzate
BR0111403A (pt) Composições que contêm policarbonato
EA200000736A1 (ru) Фармацевтические композиции
BR0213259A (pt) Método para produzir um composto bioativo apresentando uma bioatividade conhecida, e, células recombinantes
FI870873A0 (fi) Isohexid-nukleosid.
ES2104295T3 (es) Derivados ciclopeptidicos de la angiopeptina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BR0016103A (pt) Processo para a esterização induzida cataliticamente de um mono- ou polihidroxi alcanol e pelo menos um ácido carboxìlico contendo aditivos com um conteúdo de estanho residual reduzido; composições termoplásticas contendo os mesmos e processo para a preparação de uma composição termoplástica
BR9801001A (pt) Composições de revestimento resistente à abrasão dinâmica, método para produção das mesmas e artigo revestido.
BR9901399A (pt) Cepa de levedura, processo para produção de riboflavina e processo para produção de uma composição de alimento ou ração.

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO DE ACORDO COM OS ARTS. 8O, 10 E 13 DA LPI 9279/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: DESPACHO: PARA QUE A PETICAO NPRJ 020130031528 DE 12/04/2013 SEJA ACATADA COMO CUMPRIMENTO DE EXIGENCIA EM GRAU DE RECURSO (CODIGO 280 DA TABELA DE RETRIBUICAO VIGENTE), DEVERA SER EFETUADA COMPLEMENTACAO DE TAXA NO VALOR DE R$ 470,00 ( QUATROCENTOS E SETENTA REAIS).

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/505 (2006.01), C12N 15/16 (2006.0

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 03/12/2018